

Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active *Lactobacillus reuteri* NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults

Mitchell L. Jones^{1,2}, Christopher J. Martoni², Mathieu Parent² and Satya Prakash^{1*}

¹Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering and Physiology, Faculty of Medicine, Artificial Cells and Organs Research Centre, McGill University, 3775 University Street, Montreal, QC, Canada H3A 2B4

²Micropharma Limited, 141 Avenue du President Kennedy, UQAM, Biological Sciences Building, 5th Floor, Suite 5569, Montreal, QC, Canada H2X 3Y7

(Submitted 9 May 2011 – Final revision received 20 July 2011 – Accepted 21 July 2011 – First published online 9 November 2011)

Abstract

Several studies have reported limited or no reduction in serum cholesterol in response to probiotic formulations. Recently, probiotics have shown promise in treating metabolic disease due to improved strain selection and delivery technologies. The aim of the present study was to evaluate the cholesterol-lowering efficacy of a yoghurt formulation containing microencapsulated bile salt hydrolase (BSH)-active *Lactobacillus reuteri* NCIMB 30242, taken twice per d over 6 weeks, in hypercholesterolaemic adults. A total of 114 subjects completed this double-blind, placebo-controlled, randomised, parallel-arm, multi-centre study. This interventional study included a 2-week washout, 2-week run-in and 6-week treatment period. Subjects were randomised to consume either yoghurts containing microencapsulated *L. reuteri* NCIMB 30242 or placebo yoghurts. Over the intervention period, subjects consuming yoghurts containing microencapsulated *L. reuteri* NCIMB 30242 attained significant reductions in LDL-cholesterol (LDL-C) of 8.92% ($P = 0.016$), total cholesterol (TC) of 4.81% ($P = 0.031$) and non-HDL-cholesterol (HDL-C) of 6.01% ($P = 0.029$) over placebo, and a significant absolute change in apoB-100 of -0.19 mmol/l ($P = 0.049$). Serum concentrations of TAG and HDL-C were unchanged over the course of the study. Present results show that consumption of microencapsulated BSH-active *L. reuteri* NCIMB 30242 yoghurt is efficacious and safe for lowering LDL-C, TC, apoB-100 and non-HDL-C in hypercholesterolaemic subjects. The efficacy of microencapsulated BSH-active *L. reuteri* NCIMB 30242 yoghurts appears to be superior to traditional probiotic therapy and akin to that of other cholesterol-lowering ingredients.

Key words: Hypercholesterolaemia; LDL-cholesterol; Bile salt hydrolase; Microencapsulated probiotics

Coronary artery disease (CAD) is the leading cause of death in the USA, Europe, Canada and many other industrialised nations^(1,2). According to present trends in the USA, one in two healthy 40-year-old males and one in three females will develop CAD in their lifetime⁽³⁾. CVD are expected to be the main cause of death globally, due to rapidly increasing rates in developing countries and the rising incidence of obesity and diabetes in the industrialised world^(4,5). Epidemiological data reveal a log-linear relationship between increasing LDL-cholesterol (LDL-C) concentration and relative risk of CAD⁽⁶⁾. Clinical trials have confirmed this log-linear relationship, showing an almost identical pattern of risk association⁽²⁾.

Dietary recommendations and exercise are the first line of therapy for individuals with elevated LDL-C; however, using these methods only very modest reductions in LDL-C can be realised even with the highest levels of compliance⁽⁷⁾. Patients

who find it too difficult to make lifestyle modifications, or those who simply cannot realise enough LDL-C reduction, are offered statin therapy to reduce their risk profile^(8–10). Unfortunately, less than half the number of patients who qualify for lipid-modifying treatment are receiving it, and only a third of treated patients are achieving their LDL-C goal due to associated cost and other limitations⁽²⁾. Thus, an effort is underway to functionalise food products and develop nutraceuticals that can help lower LDL-C and the risk of CAD.

Probiotic bacteria are defined by the WHO as 'live microorganisms which when administered in adequate amounts confer a health benefit on the host' and are being examined for their efficacy in lowering total cholesterol (TC) and LDL-C in humans. A double-blind, randomised, placebo-controlled crossover study, by Schaafsma *et al.*⁽¹¹⁾, reported a decrease in TC and LDL-C by 4.4 and 5.4%, respectively, after consumption

Abbreviations: APA, alginate-poly-L-lysine-alginate; BSH, bile salt hydrolase; CAD, coronary artery disease; GI, gastrointestinal; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; TC, total cholesterol.

* **Corresponding author:** Dr S. Prakash, fax: +1 514 398 7461, email satya.prakash@mcgill.ca

of yoghurt enriched with *Lactobacillus acidophilus* and fructo-oligosaccharides three times daily in thirty normolipidaemic male subjects. A double-blind, randomised, placebo-controlled crossover study, by Bertolami *et al.*⁽¹²⁾, reported a decrease in TC and LDL-C by 5.3 and 6.15%, respectively, after consumption of a fermented milk product containing *Enterococcus faecium* in thirty-two subjects with mild to moderate hypercholesterolaemia. A double-blind, randomised, placebo-controlled study, by Agerbaek *et al.*⁽¹³⁾, reported a decrease in LDL-C by 10% after consumption of a fermented milk product containing *E. faecium* and two strains of *Streptococcus thermophilus*, in fifty-eight non-obese, normocholesterolaemic 44-year-old Danish men. A double-blind, randomised, placebo-controlled parallel study, by Agerholm-Larsen *et al.*⁽¹⁴⁾ reported a significant reduction in LDL-C, but only after adjusting for body weight, after consumption of a yoghurt fermented with *E. faecium* and two strains of *S. thermophilus*. While these studies have reported positive findings, several placebo-controlled studies have reported little or no effect after daily consumption of various probiotic supplements and foods containing probiotic bacteria^(15–19).

Lactobacillus reuteri NCIMB 30242 was selected for its cholesterol-lowering traits and overall strain safety using a rigorous process. Extensive *in vitro* characterisation was performed on the strain using a combination of molecular and metabolic techniques to support its safety for use in human subjects⁽²⁰⁾. One phenotypic characteristic of the strain is its intrinsic capacity to deconjugate bile acids due to expression of a bile salt hydrolase (BSH) enzyme. The BSH enzyme hydrolyses the C-24 *N*-acyl amide bond linking the free bile acid to its amino acid conjugate glycine or taurine. It has been hypothesised that deconjugation of bile acids leads to a reduction of serum cholesterol by increasing cholesterol catabolism during the formation of new bile acids, or by reducing cholesterol absorption from dietary and bile sources in the intestinal lumen^(21–23). More recently, several groups have proposed other mechanisms by which bile may act to modulate cholesterol absorption and metabolism in humans^(24–27).

Extensive research on probiotic survival in the gastrointestinal (GI) tract and in various food products has revealed reduced probiotic bacterial cell viability due to exposure to organic acids, hydrogen ions, oxygen and antibacterial components^(28,29). For this reason, the present study was designed to evaluate the cholesterol-lowering potential of alginate-poly-L-lysine-alginate (APA) microencapsulated *L. reuteri* NCIMB 30242, which allows for the delivery of highly viable and metabolically active cells to the proximal small intestine. Microencapsulation provides a physical barrier against Ig and digestive enzymes, buffers against an acidic gastric environment, concentrates the bacteria within the microcapsule and provides a microenvironment that aids in precipitation of the deconjugate^(30–32). In fact, we have shown that APA microencapsulated BSH-active *Lactobacillus plantarum* and *L. reuteri* strains maintain cell viability and bile acid deconjugation activity through sequential transit in a simulated GI model^(33,34). Furthermore, in BioF1B hamsters, a significant cholesterol-lowering effect was observed by APA microencapsulated

Lactobacillus as compared to sham (empty) APA microcapsule-treated control⁽³⁵⁾.

Despite improved pharmacotherapy for hypercholesterolaemia, a discrepancy between target cholesterol levels and those clinically realised remains. Thus, additional treatment modalities such as probiotics should be evaluated for their cholesterol-lowering efficacy and safety profile. Accordingly, the main objective of the present study was to assess the cholesterol-lowering clinical efficacy and safety of microencapsulated *L. reuteri* NCIMB 30242 supplemented in a yoghurt formulation in a double-blind, randomised, placebo-controlled, multi-centre study.

Experimental methods

Subjects

The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the central ethics committee (multi-centric ethics committee) and the local ethics committee in the Czech Republic. Written informed consent was obtained from all subjects. The trial was registered on clinicaltrials.gov, USA, identifier NCT01185795.

Otherwise healthy hypercholesterolaemic adult men and women were recruited from five centres in Prague, Czech Republic. Inclusion criteria for randomisation were otherwise healthy males and females between the ages of 18 and 74 years (inclusive); LDL-C levels >3.4 mmol/l with <15% variation between successive screening visits; TAG levels <4.0 mmol/l; BMI of 22–32 kg/m²; the ability to understand dietary procedures; judged by the investigators as motivated. Exclusion criteria for randomisation were the use of statin or other cholesterol-lowering prescription drugs within the last 6 months; use of plant sterols, *n*-3 fatty acids, fish oil, soya protein, soluble oat fibre, psyllium seed husk or other cholesterol-lowering supplements within the last 3 months; history of chronic use of alcohol (>2 drinks/d); use of systemic antibodies, corticosteroids, androgens or phenytoin; myocardial infarction, coronary artery bypass or other surgical procedures within the last 6 months; lactose intolerance or allergies to dairy products; history of angina, congestive heart failure, inflammatory bowel disease, pancreatitis or diabetes; GI, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of active lesions, chemotherapy or surgery in the past year); chronic use of probiotics or fibre laxatives (>2 doses/week), or stimulant laxatives; history of eating disorders; exercise greater than walking 15 miles/week, or an equivalent energy expense of 16 736 kJ/week (4000 kcal/week); pregnancy, breast feeding or intent to get pregnant.

Preparation of treatment and placebo yoghurts

Lactobacillus reuteri NCIMB 30242 (Cardioviva™) was propagated in an FV8 fermenter and concentrated in compliance with standard operating procedures and quality control procedures at Microbial Developments Limited (Malvern, UK). Microbiological analyses and bacterial culture purity were

confirmed immediately after each production batch. APA microcapsules containing *L. reuteri* NCIMB 30242 were prepared in compliance with standard operating procedures and quality-control procedures at Brace GmbH (Karlstein, Germany) to a viability of 5×10^9 colony-forming units/g microcapsule. Placebo and treatment yoghurts were produced and prepared at Milcom (Prague, Czech Republic) with compositions as shown in Table 1. Placebo yoghurts were filled to a weight of 125 g in plastic cups. Treatment yoghurts contained 115 g of yoghurt and 10 g of microcapsules containing BSH-active *L. reuteri* NCIMB 30242. Placebo and treatment yoghurts were produced five times during the study with the batch numbers 1 to 5. The expiry date of placebo and treatment yoghurts was maintained at 3 weeks after yoghurt production. For details of analyses of cell viability and bile salt hydrolase activity of free and microencapsulated *L. reuteri* NCIMB 30242 in simulated upper GI tract conditions, see Appendix A (to be found in the online Supplementary material; <http://journals.cambridge.org/bjn>).

Study design

The study design was double-blind, placebo-controlled, randomised, parallel-arm and multi-centred, lasting a total of 10 weeks. This included a 2-week washout period in which general dietary recommendations (Canada's Food Guide, Health Canada) were followed, a 2-week run-in period in which general dietary recommendations were followed and subjects consumed placebo yoghurts twice daily at breakfast or dinner, and a 6-week treatment period in which general recommendations were followed and subjects consumed either placebo or treatment yoghurts twice daily at breakfast or dinner. Subjects met with the investigational team at five different time points: Visit V0 (Week -4), V1 (Week -2), V2 (Week 0, randomisation and treatment baseline), V3 (Week 3, treatment midpoint) and V4 (Week 6, treatment endpoint). Dietary intake, including information on total energy, percentage total fat, percentage total carbohydrates and percentage total protein, for subjects consuming placebo yoghurts and treatment yoghurts, was measured at baseline (Week 0) and endpoint (Week 6) of the treatment period.

Sample analysis

Blood for assessment of lipid profile was collected at each visit. Serum samples were analysed enzymatically for LDL-C

(primary efficacy variable), TC, HDL-cholesterol (HDL-C), TAG and apoB-100. Absolute changes in lipid parameters for each subject at midpoint and endpoint were calculated by subtracting the baseline value (Week 0) from the midpoint (Week 3) or endpoint (Week 6) value, respectively. Relative change in lipid parameters for each subject at midpoint and endpoint was calculated by dividing the absolute change at midpoint (Week 3) or endpoint (Week 6) by baseline values (Week 0) and multiplying by 100%. Blood for assessment of safety profile was collected at visits V1 (Week -2) and V4 (Week 6, treatment endpoint). Serum biochemistry was analysed for urea, creatinine, bilirubin, aspartate aminotransferase, alanine transaminase, γ -glutamyl transpeptidase, alkaline phosphatase, glucose, Ca^{2+} , PO_4^{3-} , K^+ , Na^+ , Cl^- , HCO_3^- and lipase. Serum analysis was performed on a Dimension RxL biochemistry analyser using appropriate reagent kits (Dade Behring, Siemens, Munich, Germany). Whole blood (haematology) was analysed for Hb, haematocrit, erythrocytes, leucocytes and platelets using a Celltac F haematology analyser (Nihon Kohden, Tokyo, Japan).

Faecal samples were collected in the 3 d before visits V1 (Week -2) and V4 (treatment endpoint). Faecal deconjugated bile acid concentration was analysed on 10–15 μg of lyophilised stool samples by GLC as described by Batta *et al.*⁽³⁶⁾.

Statistical methods

The number of subjects was calculated by taking into account a critical difference in LDL-C of 0.44 (SD 0.8) mmol/l between the treatment and placebo groups with $\alpha = 5\%$ and a power of 80%. Given these constraints, fifty-three evaluable subjects per group or 106 in total were required. To take into account possible premature withdrawal, a total of 120 subjects was planned to be included for randomisation.

The primary null hypothesis was that treatment was not more effective than placebo in reducing serum LDL-C concentrations. All analyses were performed according to the intention-to-treat principle. Continuous variables are presented as means with standard errors of the mean. The Shapiro–Wilk test was used to determine if variables were parametrically distributed. Differences between groups for baseline characteristics were analysed using a one-way ANOVA for continuous variables or χ^2 test for categorical variables. Differences in dietary intake of macronutrients and faecal deconjugated bile acids between and within groups were analysed using mixed-model ANOVA. For lipid variables, multiple-linear regression was used to identify variables systematically contributing to any changes from baseline. To test the differences between groups, ANCOVA were performed to adjust for any systematic contribution to the changes from baseline using covariates identified by multiple-linear regression. Lipid parameters not accepting parametric description were analysed by means of Kruskal–Wallis tests. Data analyses were performed using SPSS software package version 17.0 (SPSS Inc., Chicago, IL, USA).

Forward, stepwise and backward selection models were completed using SAS software package version 9.2 (SAS Institute, Cary, NC, USA).

Table 1. Composition of placebo and *L. reuteri* yoghurts

	Placebo yoghurt (125 g)	<i>L. reuteri</i> yoghurt (125 g)
Protein (g)	7.9	7.2
Carbohydrates (g)	11.5	10.6
Lipids (g)	1.3	1.2
Yoghurt bacteria (CFU)*	1.25×10^9	1.15×10^9
<i>L. reuteri</i> microcapsules (g)	0	10
Microencapsulated <i>L. reuteri</i> (CFU)*	0	5.0×10^{10}
Microencapsulated <i>L. reuteri</i> (CFU)†	0	1.4×10^9

CFU, colony forming unit.

* Measured after production.

† Measured after international shipping at 4°C.

Table 2. Demographic and clinical characteristics at baseline (Mean values with their standard errors)

	Placebo yoghurt (n 58)		<i>L. reuteri</i> yoghurt (n 56)		<i>P</i> *
	Mean	SEM	Mean	SEM	
Caucasian (%)	100		100		1.00
Male (%)	34		38		0.74
Age (years)	48.79	1.77	51.89	1.81	0.22
Body weight (kg)	76.02	1.54	76.05	1.49	0.99
BMI (kg/m ²)	26.09	0.36	26.04	0.39	0.93
Systolic BP (mmHg)	133.29	0.99	134.66	1.52	0.45
Diastolic BP (mmHg)	79.97	0.76	81.48	0.81	0.17
Mean BP (mmHg)	97.74	0.65	99.21	0.89	0.19
Pulse (bpm)	76.34	0.65	76.45	0.68	0.92
Temperature (°C)	36.38	0.03	36.44	0.03	0.15
Statin intake (%)	0		0		1.00
TC (mmol/l)	6.65	0.09	6.68	0.12	0.80
LDL-C (mmol/l)	4.23	0.06	4.37	0.08	0.15
HDL-C (mmol/l)	1.48	0.05	1.42	0.05	0.44
LDL-C:HDL-C ratio	3.06	0.12	3.24	0.11	0.26
TAG (mmol/l)	1.60	0.10	1.62	0.10	0.90
Non-HDL-C (mmol/l)	5.17	0.08	5.26	0.10	0.48
ApoB-100 (mmol/l)	1.13	0.02	1.17	0.02	0.20

BP, blood pressure; bpm, beats per min; TC, total cholesterol; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol.

* One-way ANOVA for continuous variables or χ^2 test for categorical variables.

Results

Study parameters

A total of 120 subjects were randomised and 114 completed the study as part of the intention-to-treat population. One subject, randomised to the placebo group, dropped out for personal reasons and five subjects, two in the placebo group and three in the treatment group, were excluded as they did not meet the study criteria. Overall, 109 subjects completed the study as part of the per-protocol population. All subjects were considered hypercholesterolaemic and at borderline, high or very high risk of developing heart disease at baseline according to the National Cholesterol Education Program guidelines^(1,2).

Baseline characteristics of subjects

The baseline characteristics for the 114 subjects in the intention-to-treat population were evaluated and are presented in Table 2. The two groups produced by randomisation were homogeneous in terms of demographic and clinical characteristics. Male and female study subjects were equally distributed with 34:66% males–females in the placebo group and 38:62% males–females in the treatment group. There were no significant differences between groups at baseline in age, body weight, BMI, systolic, diastolic and mean blood pressure, pulse and temperature. Subjects were selected based on fasting serum LDL-C (>3.4 mmol/l) and TAG (<4.0 mmol/l). The mean serum concentrations of LDL-C at baseline were not significantly different between placebo and treatment groups (4.23 (SEM 0.06) mmol/l compared with 4.37 (SEM 0.08) mmol/l, respectively; $P=0.15$). Additionally, there were no significant differences between placebo and treatment groups for TC, HDL-C, TAG, apoB-100,

LDL-C:HDL-C and non-HDL-C. Statin and other lipid-lowering formulation intake among subjects was 0% in the 6 months before the study start date.

Dietary assessment

A dietary assessment of total energy, percentage total lipids, percentage total carbohydrates and percentage total proteins was performed at baseline (Week 0) and at the treatment endpoint (Week 6). There were no significant differences between placebo and treatment groups at baseline or endpoint, and no difference within groups over the treatment period (Table 3).

Serum lipid profile

The mean relative changes of LDL-C, TC, HDL-C, TAG, apoB-100, LDL-C:HDL-C and non-HDL-C from baseline to Week 3 and Week 6 are summarised in Table 4. The LDL-C-lowering effect observed at the 6-week endpoint of the intervention period was -0.37 (SEM 0.11) mmol/l with a significant mean change over placebo of 8.92% ($P=0.016$). Over the 6-week treatment period, other lipid-lowering effects were observed for TC of -0.77 (SEM 0.13) mmol/l, apoB-100 of -0.19 (SEM 0.03) mmol/l and non-HDL-C of -0.68 (SEM 1.11) mmol/l, and significant mean changes over placebo for TC of 4.81% ($P=0.031$) and non-HDL-C of 6.01% ($P=0.029$). Serum concentrations of TAG and HDL-C were unchanged over the course of the study. Three multivariate regression models were used to show that treatment was the primary predictor of LDL-C reduction: a stepwise selection approach showed that treatment was associated with a -0.44 mmol/l change in LDL-C ($P=0.0008$); a forward selection approach showed that treatment was associated with a -0.39 mmol/l change in LDL-C ($P=0.0027$); and a backward selection approach showed that treatment was associated with a -0.40 mmol/l change in LDL-C ($P=0.0019$). Finally, a side-by-side comparison of individual endpoint LDL-C changes from baseline indicates a clear LDL-C-reducing effect across the spectrum of responses (Fig. 1).

Table 3. Dietary total energy and macronutrient intake (Mean values with their standard errors)

	Placebo yoghurt (n 54)		<i>L. reuteri</i> yoghurt (n 53)		<i>P</i> *
	Mean	SEM	Mean	SEM	
Energy (total kJ)					
Week 0	7755.20	285.66	7780.50	238.25	0.77
Week 6	7870.36	231.38	8024.31	271.49	
Lipids (%)					
Week 0	34.89	0.68	36.15	0.74	0.51
Week 6	36.08	0.73	35.86	0.82	
Proteins (%)					
Week 0	17.91	0.39	17.72	0.35	0.83
Week 6	17.50	0.29	17.53	0.40	
Carbohydrates (%)					
Week 0	47.21	0.78	46.15	0.88	0.64
Week 6	46.43	0.72	46.63	0.84	

* Mixed-model ANOVA.

Table 4. Relative changes in lipid parameters from baseline at midpoint (Week 3) and endpoint (Week 6) (Mean values with their standard errors)

Relative change (%)	After 3 weeks consumption					After 6 weeks consumption				
	Placebo yoghurt (n 58)		<i>L. reuteri</i> yoghurt (n 55)		P	Placebo yoghurt (n 58)		<i>L. reuteri</i> yoghurt (n 56)		P
	Mean	SEM	Mean	SEM		Mean	SEM	Mean	SEM	
LDL-C	1.49	1.87	-2.57	1.89	0.165*	1.38	2.14	-7.54	2.38	0.016*
TC	-2.28	1.55	-4.95	1.77	0.354†	-5.76	1.56	-10.57	1.79	0.031*
HDL-C	-1.73	2.90	-1.07	2.14	0.982*	-3.30	2.71	-3.20	3.23	0.808*
TAG	25.22	8.88	1.86	4.89	0.084†	-0.40	6.15	18.80	10.03	0.230†
ApoB-100	-7.12	1.96	-10.89	2.27	0.545*	-8.21	2.43	-15.02	2.34	0.092*
LDL-C:HDL-C	8.62	4.24	0.03	2.23	0.190†	10.51	4.55	0.92	3.91	0.170†
Non-HDL-C	-2.02	1.89	-6.00	1.96	0.172*	-6.30	1.77	-12.31	1.88	0.029*

LDL-C, LDL-cholesterol; TC, total cholesterol; HDL-C, HDL-cholesterol.

* ANCOVA adjusted by baseline values.

† Kruskal-Wallis test.

Faecal assessment

Faecal samples collected before treatment (Week -2) and at endpoint (Week 6) were analysed for faecal deconjugated bile acid concentration. A total of forty samples collected was deemed adequate for analysis; twenty-one in the treatment group and nineteen in the placebo group. The mean faecal deconjugated bile acid concentration was not found to be significantly different between groups, before treatment and at endpoint, or within groups over the treatment period (Table 5).

Safety parameters

Biochemical markers of safety were measured at baseline and endpoint and analysed for significant changes. Haematologic markers were assessed by complete blood cell count, platelets, haematocrit and Hb; kidney function was determined by urea and creatinine; liver function was

determined by alanine transaminase, aspartate aminotransferase, γ -glutamyl transpeptidase, alkaline phosphatase and bilirubin; pancreatic function was determined by lipase; endocrine function was determined by glucose, Ca^{2+} and PO_4^{3-} ; and electrolyte balance was determined by K^+ , Na^+ , Cl^- and HCO_3^- . Results show that the placebo and treatment groups were comparable for biomarkers of safety at the study endpoint, and the number of subjects with clinically significant values outside the normal range was determined to be six subjects in the placebo group and one subject in the treatment group. No changes in biochemical markers of safety were considered to be a result of treatment (data not shown).

Discussion

This double-blind, randomised, placebo-controlled, parallel-arm, multi-centre study demonstrates the cholesterol-lowering




Fig. 1. LDL-cholesterol (LDL-C) response showing per subject percentage change from baseline to endpoint of treatment period for groups consuming placebo yoghurt (n 58, □) and *Lactobacillus reuteri* NCIMB 30242 yoghurt (n 56, ■) in the intention-to-treat population.

Table 5. Faecal deconjugated bile acids
(Mean values with their standard errors)

	Placebo yoghurt (n 19)		<i>L. reuteri</i> yoghurt (n 21)		<i>P</i> *
	Mean	SEM	Mean	SEM	
Deconjugated bile acids (μmol/g)					
Week 0	3.08	0.56	3.33	0.48	0.94
Week 6	3.26	0.54	2.85	0.42	

* Mixed-model ANOVA.

effect of a novel microencapsulated BSH-active probiotic over 6 weeks. Subjects consuming yoghurts containing microencapsulated *L. reuteri* NCIMB 30242 attained significant reductions over placebo in LDL-C of 8.92%, TC of 4.81% and non-HDL-C of 6.01%, and a significant absolute change in apoB-100 of -0.19 (SEM 0.03) mmol/l over the intervention period. Serum concentrations of TAG and HDL-C were unchanged over the course of the study. As well, three multivariate regression models were used to show that treatment was the primary predictor of LDL-C reduction. Finally, a side-by-side comparison of individual LDL-C responses at the study endpoint indicates that despite a proportion of subjects who experienced elevated LDL-C values, an LDL-C-lowering effect was observed over the spectrum of LDL-C responses (Fig. 1).

When examining the cholesterol-lowering trend over the course of the study, it is apparent that the time to maximal therapeutic effect may be longer than other cholesterol-lowering therapies^(8,37–41). Although only baseline, 3- and 6-week data were collected, a cholesterol-lowering trend was observed over the course of the study, indicating that maximal therapeutic effect may not have been reached by the study endpoint. Thus, future studies should evaluate the cholesterol-lowering efficacy of *L. reuteri* NCIMB 30242 at later time points. Also, subjects on statin monotherapy were excluded from the study to accurately determine lipid-lowering efficacy of the microencapsulated probiotic alone; however, evidence exists for improved effectiveness of dietary cholesterol-reducing agents in subjects having high cholesterol absorption and low biosynthesis⁽⁴²⁾. Thus, the potential for greater cholesterol reductions in subjects with reduced cholesterol biosynthesis should be explored.

One possible mechanism of action for cholesterol-lowering with BSH-active probiotics is that increased intra-luminal BSH activity may lead to increased excretion of deconjugated bile acids and subsequent removal of serum cholesterol by the liver replacing bile acids lost from the enterohepatic recirculation (*de novo* synthesis of bile acids by 7 α -hydroxylase catabolism of cholesterol)^(22,43). The conversion of cholesterol to bile acids in the liver and their subsequent secretion and faecal excretion provides the major route for elimination of excess cholesterol. Previously, we have shown that APA microencapsulated BSH-active *L. plantarum* and *L. reuteri* strains maintain cell viability and bile acid deconjugating activity in simulated upper GI conditions^(33,34). In the present study, despite significant reductions in serum LDL-C, no significant change in faecal deconjugated bile acid excretion was seen in the

samples collected. A recent randomised, placebo-controlled clinical trial by Ooi *et al.*⁽⁴⁴⁾ showed a significant reduction in plasma TC and LDL-C as a result of synbiotic capsule feeding containing BSH-active *L. acidophilus* CHO-220 and inulin. However, no significant differences in the levels of plasma deconjugated primary or plasma deconjugated secondary bile acids were observed over the 12-week treatment period. The authors postulated that the BSH activity of *L. acidophilus* CHO-220, shown *in vitro*, either was not exhibited in human subjects or was too minimal to produce an observed effect.

Previous studies^(43,45,46) in animals have shown hypocholesterolaemic effects of BSH-active probiotics along with increased bile acid excretion. In a porcine model, the strain *B. animalis* DN-173010, chosen from thirty-eight strains for its bile acid deconjugation capacity, was shown to increase serum deconjugated bile acids after 1 and 2 weeks of treatment⁽⁴⁷⁾. It has been suggested that increasing bile acid deconjugation activity in the small intestine could render the deconjugated primary bile acids more susceptible to 7 α -dehydroxylation activity by the resident microflora, potentially leading to increased secondary bile acids. However, an increase in the formation of secondary bile acids was not observed in the portal vein of pigs⁽⁴⁷⁾ or in the faeces of healthy human subjects⁽⁴⁸⁾ upon *B. animalis* DN-173010 intervention. Evidence for the expression of 7 α -dehydroxylase in lactic acid bacteria has not been reported in the literature, and is a genotype that appears to be limited to *Enterobacter* and *Clostridium* species within the gut microflora⁽⁴⁹⁾. Furthermore, it has also been reported that active and passive absorption of bile acids complement one another and bring about nearly complete absorption of bile acid, whether conjugated or deconjugated, from the small-intestinal contents of rodents⁽⁵⁰⁾. Therefore, one hypothesis states that deconjugation of bile acids proximal to the terminal ileum does not disrupt the enterohepatic circulation of bile acids but rather alters the bile acid pool in circulation. Future studies should therefore assess the complete bile acid profile in circulation as well as in faeces.

A study by Jeun *et al.*⁽⁴⁵⁾ demonstrated increased gene expression changes, together with increased bile acid excretion, on account of *L. plantarum* feeding in mice. Several mechanisms were postulated to explain the hypocholesterolaemic effect *in vivo*, including inhibition of hepatic cholesterol synthesis, induction of cellular LDL-C uptake, decreased dietary cholesterol uptake and elevation of bile acid excretion. Given the result in the present study, other mechanisms of action were considered, including down-regulation of

farnesoid X receptor (FXR) and consequent effect of liver X receptor (LXR) down-regulation and deconjugated bile acids on adenosine triphosphate-binding cassette G5/G8 heterodimer cholesterol efflux in hepatocytes and enterocytes (Fig. 2). Such a mechanism of action would result in a significant increase in faecal total neutral sterol excretion; thus, future studies should also evaluate neutral sterol excretion in faeces.

Analysis of safety parameters did not show deleterious effects of consuming yoghurts containing microencapsulated *L. reuteri* NCIMB 30242. There were more subjects with safety parameters that fell outside the clinically normal range in the placebo group, as compared to the treatment group, at the study endpoint. While there were no significant changes in leucocyte count, a crude measure of inflammation, future studies should substantiate this result by looking at acute-phase reactants such as C-reactive protein which have important cardiovascular implications^(51–55).

Future studies should continue to look at improving delivery technologies for BSH-active probiotics. Microencapsulation technologies, including APA microencapsulation, should

continue to focus on minimising microcapsule diameter, for improved functionality and palatability, while maximising cell loading, ultimately resulting in minimising the dose size required for clinical efficacy.

In summary, several probiotic clinical studies have shown some cholesterol-lowering efficacy^(11–14), while others have shown negative results^(15–19), which may have been due to poor strain selection, method of delivery or clinical design. In most cases, BSH activity is not mentioned as a characteristic of the strain administered. Previously, a BSH-active strain was shown to significantly decrease TC and LDL-C in humans, when taken as a synbiotic⁽⁴⁴⁾. For the present study, *L. reuteri* NCIMB 30242 was selected using a rigorous cholesterol-lowering and strain safety screening process, including BSH activity, and was delivered using a gastroprotective microencapsulation technology. The present results support efficacy and safety of the formulation in lowering LDL-C, TC, apoB-100 and non-HDL-C in hypercholesterolaemic adults over 6 weeks. The hypocholesterolaemic effect of microencapsulated *L. reuteri* NCIMB 30242 in yoghurt compares favourably with other cholesterol-lowering food ingredients⁽³⁸⁾.




Fig. 2. Bile salt hydrolase (BSH)-active microencapsulated *Lactobacillus reuteri* NCIMB 30242, by reducing the concentration of bile acids (BA) returning to the liver or by changing the BA pool profile, may down-regulate farnesoid X receptor (FXR) leading to increased catabolism of cholesterol and synthesis of BA by 7α-hydroxylase. Down-regulation of FXR may lead to up-regulation of liver X receptor (LXR) which has been shown to enhance reverse cholesterol transport, improve glycaemic control⁽²²⁾ and increase the export of free cholesterol from cells through up-regulation of the adenosine triphosphate-binding cassette (ABC) transports⁽²²⁾. Particularly, ABCG5 and ABCG8 function as heterodimers (ABCG5/G8) at the apical membrane of enterocytes and hepatocytes and limit the accumulation of cholesterol by transporting it into the gastrointestinal (GI) lumen and bile canaliculi. BA, together with cholesterol, promote an active conformation of ABCG5/G8 and increase the efflux of cholesterol⁽²³⁾. Thus, there may be a net efflux of cholesterol by enterocytes and hepatocytes into the GI lumen and bile canaliculi⁽²³⁾ resulting in a decrease in serum cholesterol and an increase in cholesterol excretion in faeces. LDL-C, LDL-cholesterol; LDL-R, LDL receptor; SHP, small heterodimer partner; CBA, conjugated BA.

Acknowledgements

The authors thank J. Lahovský, A. Vajikova, N. Barannikova, K. Beber, L. Coupal and S. Grover for their contribution to the study. The authors also thank all volunteers who participated in the study. M. L. J., S. P. and C. J. M. designed the study and prepared the manuscript; J. Lahovský, A. Vajikova and N. Barannikova conducted the research; K. Beber, M. P., L. Coupal and S. Grover performed the statistical analysis. All authors have read and approved the final manuscript. This work was supported by Micropharma Limited. M. L. J., C. J. M., M. P. and S. P. are with Micropharma Limited and report a conflict of interest. All other contributors have no conflicts of interest to report.

References

- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* **106**, 3143–3421.
- Grundy SM, Cleeman JI, Merz CNB, *et al.* (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* **110**, 227–239.
- Durrington P (2003) Dyslipidaemia. *Lancet* **362**, 717–731.
- Murray CJ & Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet* **349**, 1436–1442.
- World Health Organization (2002) *The World Health Report 2002 – Reducing Risks, Promoting Healthy Life*. Geneva: WHO.
- Jacobson TA (2000) ‘The lower the better’ in hypercholesterolemia therapy: a reliable clinical guideline? *Ann Intern Med* **133**, 549–554.
- Talbert RL (2002) New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III. *Am J Manag Care* **8**, S301–S307.
- Stancu C & Sima A (2001) Statins: mechanism of action and effects. *J Cell Mol Med* **5**, 378–387.
- Oliver MF, Defeyter PJ, Lubsen J, *et al.* (1994) Effect of simvastatin on coronary atheroma – the Multicenter Anti-Atheroma Study (Maas). *Lancet* **344**, 633–638.
- Pedersen TR, Kjekshus J, Berg K, *et al.* (1994) Randomized trial of cholesterol-lowering in 4444 patients with coronary-heart-disease – the Scandinavian Simvastatin Survival Study (4S). *Lancet* **344**, 1383–1389.
- Schaafsma G, Meuling WJ, van Dokkum W, *et al.* (1998) Effects of a milk product, fermented by *Lactobacillus acidophilus* and with fructo-oligosaccharides added, on blood lipids in male volunteers. *Eur J Clin Nutr* **52**, 436–440.
- Bertolami MC, Faludi AA & Batlouni M (1999) Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. *Eur J Clin Nutr* **53**, 97–101.
- Agerbaek M, Gerdes LU & Richelsen B (1995) Hypocholesterolemic effect of a new fermented milk product in healthy middle-aged men. *Eur J Clin Nutr* **49**, 346–352.
- Agerholm-Larsen L, Raben A & Haulrik N (2000) Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. *Eur J Clin Nutr* **54**, 288–297.
- Andersson H, Bosaeus I, Ellegard L, *et al.* (1995) Effects of low-fat milk and fermented low-fat milk on cholesterol absorption and excretion in ileostomy subjects. *Eur J Clin Nutr* **49**, 274–281.
- de Roos NM, Schouten G & Katan MB (1999) Yoghurt enriched with *Lactobacillus acidophilus* does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. *Eur J Clin Nutr* **53**, 277–280.
- Greany KA, Bonorden MJ, Hamilton-Reeves JM, *et al.* (2008) Probiotic capsules do not lower plasma lipids in young women and men. *Eur J Clin Nutr* **62**, 232–237.
- Lewis SJ & Burmeister S (2005) A double-blind placebo-controlled study of the effects of *Lactobacillus acidophilus* on plasma lipids. *Eur J Clin Nutr* **59**, 776–780.
- Lin SY, Ayres JW, Winkler L Jr, *et al.* (1989) Lactobacillus effects on cholesterol: in vitro and in vivo results. *J Dairy Sci* **72**, 2885–2899.
- Branton WB, Jones ML, Tomaro-Duchesneau C, *et al.* (2011) *In vitro* characterization and safety of the probiotic strain *Lactobacillus reuteri* cardioviva NCIMB 30242. *Int J Probiotics Prebiotics* **6**, 1–12.
- Taranto MP, Sesma F, Holgado APD, *et al.* (1997) Bile salts hydrolase plays a key role on cholesterol removal by *Lactobacillus reuteri*. *Biotechnol Lett* **19**, 845–847.
- De Smet I, Van Hoorde L, De Saeyer M, *et al.* (1994) In vitro study of bile salt hydrolase (BSH) activity of BSH isogenic *Lactobacillus plantarum* 80 strains and estimation of cholesterol lowering through enhanced BSH activity. *Microb Ecol Health Dis* **7**, 315–329.
- De Smet I, Van Hoorde L, Vande WM, *et al.* (1995) Significance of bile salt hydrolytic activities of lactobacilli. *J Appl Bacteriol* **79**, 292–301.
- Davidson MH (2008) Interrupting bile-acid handling and lipid and glucose control: effects of colestevlam on glucose levels. *J Clin Lipid* **2**, S29–S33.
- Johnson BJ, Lee JY, Pickert A, *et al.* (2010) Bile acids stimulate ATP hydrolysis in the purified cholesterol transporter ABCG5/G8. *Biochemistry* **49**, 3403–3411.
- Thomas C, Pellicciari R, Pruzanski M, *et al.* (2008) Targeting bile-acid signalling for metabolic diseases. *Nat Rev Drug Discov* **7**, 678–693.
- Watanabe M, Houten SM, Matak C, *et al.* (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* **439**, 484–489.
- Holzappel WH, Haberer P, Snel J, *et al.* (1998) Overview of gut flora and probiotics. *Int J Food Microbiol* **41**, 85–101.
- Huang Y & Adams MC (2004) In vitro assessment of the upper gastrointestinal tolerance of potential probiotic dairy propionibacteria. *Int J Food Microbiol* **91**, 253–260.
- Chang TMS (2005) Therapeutic applications of polymeric artificial cells. *Nature Rev Drug Discov* **4**, 221–235.
- Gugerli R, Cantana E, Heinzen C, *et al.* (2002) Quantitative study of the production and properties of alginate/poly-L-lysine microcapsules. *J Microencapsul* **19**, 571–590.
- Jones ML, Chen HM, Wei OY, *et al.* (2004) Microencapsulated genetically engineered *Lactobacillus plantarum* 80 (pCBH1) for bile acid deconjugation and its implication in lowering cholesterol. *J Biomed Biotechnol* **1**, 61–69.
- Martoni C, Bhatena J, Jones ML, *et al.* (2007) Investigation of microencapsulated BSH active *Lactobacillus* in the simulated human GI tract. *J Biomed Biotechnol* **2007**, 13684.
- Martoni C, Bhatena J, Urbanska AM, *et al.* (2008) Microencapsulated bile salt hydrolase producing *Lactobacillus reuteri* for oral targeted delivery in the gastrointestinal tract. *Appl Microbiol Biotechnol* **81**, 225–233.

35. Bhatena J, Martoni C, Kulamarva A, *et al.* (2009) Orally delivered microencapsulated live probiotic formulation lowers serum lipids in hypercholesterolemic hamsters. *J Med Food* **12**, 310–319.
36. Batta AK, Salen G, Batta P, *et al.* (2002) Simultaneous quantitation of fatty acids, sterols and bile acids in human stool by capillary gas-liquid chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci* **775**, 153–161.
37. Andrews TC, Ballantyne CM, Hsia JA, *et al.* (2001) Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. *Am J Med* **111**, 185–191.
38. Demonty I, Ras RT, van der Knaap HC, *et al.* (2009) Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. *J Nutr* **139**, 271–284.
39. Patel J, Sheehan V & Gurk-Turner C (2003) Ezetimibe (Zetia): a new type of lipid-lowering agent. *Proc (Bayl Univ Med Cent)* **16**, 354–358.
40. Hou R & Goldberg AC (2009) Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. *Endocrinol Metab Clin North Am* **38**, 79–97.
41. Gagne C, Gaudet D & Bruckert E (2002) Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. *Circulation* **105**, 2469–2475.
42. Ostlund RE Jr (2004) Phytosterols and cholesterol metabolism. *Curr Opin Lipidol* **15**, 37–41.
43. De Smet I, De Boever P & Verstraete W (1998) Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity. *Br J Nutr* **79**, 185–194.
44. Ooi LG, Ahmad R, Yuen KH, *et al.* (2010) *Lactobacillus acidophilus* CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters. *J Dairy Sci* **93**, 5048–5058.
45. Jeun J, Kim S, Cho SY, *et al.* (2010) Hypocholesterolemic effects of *Lactobacillus plantarum* KCTC3928 by increased bile acid excretion in C57BL/6 mice. *Nutrition* **26**, 321–330.
46. Kumar R, Grover S & Batish VK (2011) Hypocholesterolaemic effect of dietary inclusion of two putative probiotic bile salt hydrolase-producing *Lactobacillus plantarum* strains in Sprague–Dawley rats. *Br J Nutr* **105**, 561–573.
47. Lepercq P, Relano P, Cayuela C, *et al.* (2004) *Bifidobacterium animalis* strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. *Scand J Gastroenterol* **39**, 1266–1271.
48. Marteau P, Cuillerier E, Meance S, *et al.* (2002) *Bifidobacterium animalis* strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. *Aliment Pharmacol Ther* **16**, 587–593.
49. Begley M, Hill C & Gahan CGM (2006) Bile salt hydrolase activity in probiotics. *Appl Environ Microbiol* **72**, 1729–1738.
50. Schiff ER, Small NC & Dietschy JM (1972) Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. *J Clin Invest* **51**, 1351–1362.
51. Ridker PM, Glynn RJ & Hennekens CH (1998) C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. *Circulation* **97**, 2007–2011.
52. Ridker PM, Hennekens CH, Buring JE, *et al.* (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* **342**, 836–843.
53. Ridker PM, Rifai N, Clearfield M, *et al.* (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med* **344**, 1959–1965.
54. Ridker PM, Stampfer MJ & Rifai N (2001) Novel risk factors for systemic atherosclerosis – a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. *JAMA* **285**, 2481–2485.
55. Roberts WL (2004) CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease – Application to Clinical and Public Health Practice – Laboratory tests available to assess inflammation performance and standardization – A background paper. *Circulation* **110**, E572–E576.